A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma

NCT02981342 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Abemaciclib
DRUG: LY3023414
DRUG: Gemcitabine
DRUG: Capecitabine

Sponsor

Eli Lilly and Company